Skip to content

US · CELZ · BIOTECHNOLOGY

Creative Medical Technology Holdings, Inc. (CELZ) intrinsic value and stock valuation

$0.40as of 2026-11-21 · Mkt cap 1.73M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Creative Medical Technology Holdings, Inc. DCF and intrinsic value

InvestorsCraft values CELZ with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from CELZ’s statements →

Creative Medical Technology Holdings, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Phoenix, AZ 85012 creativemedicaltechnology.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$10K-42.6% 5y CAGRd
20112025
Net income
-$-6M
20112025
Free cash flow
-$-5.86M
20112025
Total equity
$7.52M
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$10K$10K$10K$90K$90K
Operating income-$-6.14M-$-5.74M-$-5.62M-$-10.24M-$-3.13M
Net income-$-6M-$-5.49M-$-5.29M-$-10.14M$19.2M
EPSd-$-2.52M-$-3.71M-$-3.75M-$-9.3M$60M
Operating cash flow-$-5.86M-$-5.3M-$-8.03M-$-7.8M-$-2.22M
Capital expenditure-$0.00$0.00-$-100K$0.00$0.00
Free cash flow-$-5.86M-$-5.3M-$-8.13M-$-7.8M-$-2.22M
Total assets$7.81M$6.67M$10.7M$19.2M$11.3M
Total debt$10K$0.00$0.00$0.00$0.00
Net debt-$-7.19M-$-5.94M-$-3.47M-$-8.32M-$-10.72M
Total equity$7.52M$6.34M$10.3M$15.9M$10.2M
Cash and short-term investments$7.21M$5.94M$9.99M$18.4M$10.7M
Income statement
20252024202320222021
Revenue$10K$10K$10K$90K$90K
Cost of revenue$0.00$0.00$0.00$30K$50K
Gross profit$0.00$10K$10K$60K$40K
Research and development expenses$2.26M$2.4M$1.97M$6.27M$110K
Selling, general and administrative expenses$3.76M$3.24M$3.56M$3.94M$2.96M
Other expenses$120K$110K$90K$90K$90K
Operating expenses$6.15M$5.75M$5.63M$10.3M$3.17M
Cost and expenses$6.15M$5.75M$5.63M$10.3M$3.21M
Interest income$150K$250K$330K$100K$0.00
Interest expense$0.00$0.00$0.00$0.00$4.28M
Depreciation and amortization$120K$110K$90K$90K$90K
Ebitda-$-6.02M-$-5.38M-$-5.19M-$-10.05M$23.6M
Operating income-$-6.14M-$-5.74M-$-5.62M-$-10.24M-$-3.13M
Total other income/expenses, net$150K$250K$330K$100K$22.3M
Income before tax-$-6M-$-5.49M-$-5.29M-$-10.14M$19.2M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-6M-$-5.49M-$-5.29M-$-10.14M$19.2M
Weighted average shares outstanding$2.38M$1.48M$1.41M$1.09M$260K
Weighted average diluted shares outstanding$2.38M$1.48M$1.41M$1.09M$320K
Balance sheet
20252024202320222021
Cash and short-term investments$7.21M$5.94M$9.99M$18.4M$10.7M
Net receivables$50K$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$10K$10K$10K
Total current assets$7.4M$6.14M$10.3M$18.8M$10.7M
Property, plant and equipment, net$0.00$0.00$0.00$0.00$0.00
Goodwill and intangible assets$410K$530K$440K$440K$530K
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$410K$530K$440K$440K$530K
Total assets$7.81M$6.67M$10.7M$19.2M$11.3M
Accounts payable$270K$270K$320K$3.27M$760K
Short-term debt$10K$0.00$0.00$0.00$0.00
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$280K$330K$370K$3.32M$1.05M
Long-term debt$0.00$0.00$0.00$0.00$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$0.00$0.00$0.00$0.00$0.00
Capital lease obligations$0.00$0.00$0.00$0.00$0.00
Total liabilities$280K$330K$370K$3.32M$1.05M
Common stock$0.00$0.00$0.00$0.00$10K
Retained earnings-$-70.59M-$-64.59M-$-59.1M-$-53.81M-$-43.67M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$7.52M$6.34M$10.3M$15.9M$10.2M
Total investments$0.00$0.00$6.52M$10.1M$0.00
Total debt$10K$0.00$0.00$0.00$0.00
Net debt-$-7.19M-$-5.94M-$-3.47M-$-8.32M-$-10.72M
Cash flow statement
20252024202320222021
Net income-$-6M-$-5.49M-$-5.29M-$-10.14M$19.2M
Depreciation and amortization$120K$110K$90K$90K$90K
Stock-based compensation$0.00$40K$40K$70K$600K
Change in working capital$10K$50K-$-2.84M$2.19M$250K
Accounts receivable$0.00$0.00$0.00$0.00-$0.00
Inventory$0.00$0.00$0.00$0.00-$-10K
Accounts payable-$0.00-$-40K-$-2.95M$2.51M$410K
Net cash provided by operating activities-$-5.86M-$-5.3M-$-8.03M-$-7.8M-$-2.22M
Investments in property, plant and equipment$0.00-$-200K-$-100K$0.00$0.00
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-50K$6.32M$3.45M-$-10.08M$0.00
Common stock issued$7.17M$1.63M$0.00$15.5M$14.8M
Common stock repurchased-$-10K-$-170K-$-270K$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$7.17M$1.45M-$-270K$15.5M$12.8M
Net change in cash$1.27M$2.47M-$-4.85M-$-2.4M$10.6M
Cash at end of period$7.21M$5.94M$3.47M$8.32M$10.7M
Operating cash flow-$-5.86M-$-5.3M-$-8.03M-$-7.8M-$-2.22M
Capital expenditure-$0.00$0.00-$-100K$0.00$0.00
Free cash flow-$-5.86M-$-5.3M-$-8.13M-$-7.8M-$-2.22M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Creative Medical Technology Holdings, Inc.

        Creative Medical Technology Holdings, Inc., a biotechnology firm based in Phoenix, Arizona, specializes in advancing adult stem cell treatments. The company's core focus spans several medical fields, including immunology, urology, orthopedics, and neurology. Among its therapeutic offerings are CaverStem, designed to address erectile dysfunction; FemCelz, which aims to restore genital sensitivity and alleviate dryness; StemSpine, developed to treat chronic lower back pain; ImmCelz, intended for stroke patients; and OvaStem, a solution for female infertility.

        CEO
        Timothy Warbington
        Employees
        4
        Beta
        1.88

        Explore

        Frequently asked questions

        What is the intrinsic value of Creative Medical Technology Holdings, Inc. (CELZ)?

        InvestorsCraft does not currently publish an intrinsic value for CELZ. How the IC value is calculated.

        Is CELZ undervalued?

        InvestorsCraft does not publish an undervaluation signal for CELZ at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.